

Supplemental Table 3

Assay	BALB/cJ		C57BL/6J		NOD/ShiLtJ		PWK/PhJ		SPRET/EiJ		all combined	
	notx	KLA	notx	KLA	notx	KLA	notx	KLA	notx	KLA	notx	KLA
ATAC-seq	18,265	17,667	33,335	33,269	29,763	28,561	50,609	50,988	74,577	74,136	88,711	89,651
PU.1	64,801	77,387	81,308	65,435	69,385	53,078	59,522	55,603	74,941	44,886	117,728	101,314
C/EBP β	46,074	52,816	33,545	39,471	53,444	31,884	36,926	41,871	16,180	22,684	78,869	80,755
CJUN	51,558	34,215	23,083	43,290	50,216	73,955	35,895	43,748	29,676	40,113	79,478	94,058
P65	39,001	27,180	43,093	55,406	49,172	68,088	41,703	34,329	10,051	53,698	80,585	100,642
H3K27ac	28,364	42,585	37,779	40,206	22,723	24,441	39,526	56,549	34,776	28,951	81,437	92,560
H3K4me2	50,323	49,310	38,912	35,291	44,105	39,378	46,742	59,643	44,101	41,619	95,909	95,472

Table S3 (related to Figure 3). Summary of sequencing assays. Number of features (peaks or regions) identified for each of assay (ATAC-seq, PU.1 ChIP-seq, CEBP β ChIP-seq, CJUN ChIP-seq, P65 ChIP-seq, H3K27ac ChIP-seq and H3K4me2 ChIP-seq) in the five strains of BMDMs under notx and KLA-treated conditions for 1 hour after IDR, as well as the union of features per experiment.

Supplemental Table 6

	all CRDs	strain-specific	strain-similar	unclear
ATAC-seq notx	3439	3360	8	71
ATAC-seq KLA	3891	3889	0	2
PU.1 notx	438	393	15	30
PU.1 KLA	548	425	33	90
CEBP β notx	793	791	0	2
CEBP β KLA	388	377	1	10
CJUN notx	336	326	0	10
CJUN KLA	538	530	3	5
P65 KLA	719	694	3	22

Table S6 (related to Figure 5). Summary of CRDs. List of all CRDs for all assays and treatments, as well as number of CRDs that are strain-specific and strain-similar.